Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Svenningsson, Anders ^a   Falk, Eva ^b   Celius, Elisabeth G ^c   Fuchs, Siegrid ^d   Schreiber, Karen ^e   Berkö, Sara ^b   Sun, Jennifer ^f   Penner, Iris Katharina ^g  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b BiogenIdec Sweden AB ^*  (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF GRAZ   (Austria)

^e University of Copenhagen   (Denmark)

^f BIOGEN   (United States)

^g UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY ANALYSIS; SOMNOLENCE; WALKING SPEED;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COGNITION; DEPRESSION; FATIGUE; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRES; WALKING;

EID: 84875281260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058643     Document Type: Article

References (31)

1. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ, (1994) The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences 21: 9-14.
2. Wood B, van der Mei I, Ponsonby AL, Pittas F, Quinn S, et al. (2012) Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Multiple sclerosis 19 (2):: 217-224.
3. Amato MP, Portaccio E, (2012) Management options in multiple sclerosis-associated fatigue. Expert opinion on pharmacotherapy 13: 207-216.
4. Comi G, Leocani L, Rossi P, Colombo B, (2001) Physiopathology and treatment of fatigue in multiple sclerosis. Journal of Neurology 248: 174-179.
5. Whitaker J, Mitchell G (1997) Clinical features of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, editors. Multiple Sclerosis Clinical and Pathogenetic Basis. London: Chapman and Hall Medical. pp. 3-19.
6. Sepulcre J, Masdeu JC, Goñi J, Arrondo G, Vélez de Mendizábal N, et al. (2009) Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Multiple Sclerosis 15: 337-344.
7. Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, et al. (2010) Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Archives of Neurology 67: 447-453.
8. Yaldizli Ö, Glassl S, Sturm D, Papadopoulou A, Gass A, et al. (2011) Fatigue and progression of corpus callosum atrophy in multiple sclerosis. Journal of neurology 258: 2199-2205.
9. Filippi M, Rocca MA, Colombo B, Falini A, Codella M, et al. (2002) Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage 15: 559-567.
10. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, et al. (1997) Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: A 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48: 1566-1571.
11. Bakshi R, Shaikh ZA, Miletich R, Czarnecki D, Dmochowski J, et al. (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Multiple Sclerosis 6: 181-185.
12. Bergamaschi R, Romani A, Versino M, Poli R, Cosi V, (1997) Clinical aspects of fatigue in multiple sclerosis. Functional Neurology 12: 247-251.
13. Multiple Sclerosis Council for Clinical Practice Guidelines (1998) Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America.
14. Penner IK, Raselli C, Stocklin M, Opwis K, Kappos L, et al. (2009) The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Multiple sclerosis 15: 1509-1517.
15. Melanson M, Grossberndt A, Klowak M, Leong C, Frost EE, et al. (2010) Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. The International journal of neuroscience 120: 631-640.
16. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, et al. (2004) The effect of immunomodulatory treatment on multiple sclerosis fatigue. Journal of neurology, neurosurgery, and psychiatry 75: 1045-1047.
17. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, et al. (2011) Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Multiple sclerosis 17: 991-1001.
18. Ziemssen T, Hoffman J, Apfel R, Kern S, (2008) Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health and quality of life outcomes 6: 67.
19. Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, et al. (2012) Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLOS one 7: e35843.
20. Elbers RG, Rietberg MB, van Wegen EE, Verhoef J, Kramer SF, et al. (2011) Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 21 (6):: 925-944.
21. Putzki N, Yaldizli O, Tettenborn B, Diener HC, (2009) Multiple sclerosis associated fatigue during natalizumab treatment. Journal of the neurological sciences 285: 109-113.
22. Yildiz M, Tettenborn B, Putzki N, (2011) Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. European neurology 65: 231-232.
23. Krupp LB, (2003) Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS drugs 17: 225-234.
24. Gold SM, Irwin MR, (2009) Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunology and allergy clinics of North America 29: 309-320.
25. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, et al. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Journal of neuroimmunology 72: 155-161.
26. Miller AH, Maletic V, Raison CL, (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological psychiatry 65: 732-741.
27. Gold SM, Kruger S, Ziegler KJ, Krieger T, Schulz KH, et al. (2011) Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. Journal of neurology, neurosurgery, and psychiatry 82: 814-818.
28. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, et al. (2006) Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? Journal of neurology, neurosurgery, and psychiatry 77: 34-39.
29. Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, et al. (2004) Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Multiple sclerosis 10: 165-169.
30. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, et al. (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68: 1390-1401.
31. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.